Status:
COMPLETED
Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop...
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Hypertrophic Cardiomyopathy
Eligibility:
All Genders
5-20 years
Phase:
PHASE1
Brief Summary
Several studies have shown that specialized pacemaking devices (DDD pacing) can improve the symptoms associated with hypertrophic cardiomyopathy (HCM) in adults. In addition, studies have also shown t...
Detailed Description
Several studies have shown that dual chamber (DDD) pacemaker therapy relieves LV outflow obstruction and improves symptoms in most adult patients with obstructive hypertrophic cardiomyopathy (HCM). It...
Eligibility Criteria
- INCLUSION CRITERIA: DDD Pacemaker Therapy
Children of either gender, aged 5 to 15 years.
Presence of LV hypertrophy and LV outflow obstruction.
EXCLUSION CRITERIA: DDD Pacemaker Therapy
Other systemic disease that prevent evaluation by echocardiography or cardiac catheterization.
Chronic atrial fibrillation.
Positive pregnancy test.
INCLUSION CRITERIA: Cohort Study
Children of either gender, 5 to 20 years (children greater than 15 years will be included if there is access to reliable previous catheterization data).
Presence of LV hypertrophy and LV obstruction.
EXCLUSION CRITERIA: Cohort Study
Other systemic disease that prevent evaluation by echocardiography or cardiac catheterization.
Chronic atrial fibrillation.
Positive pregnancy test.
Key Trial Info
Start Date :
October 6 1993
Trial Type :
INTERVENTIONAL
End Date :
July 23 2008
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00001396
Start Date
October 6 1993
End Date
July 23 2008
Last Update
July 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892